Mutation spectrum of Egyptian children with cystic fibrosis by Walaa Aboulkasem Shahin et al.
Shahin et al. SpringerPlus  (2016) 5:686 
DOI 10.1186/s40064-016-2338-7
RESEARCH
Mutation spectrum of Egyptian children 
with cystic fibrosis
Walaa Aboulkasem Shahin1*, Dina Ahmed Mehaney2 and Mona Mostafa El‑Falaki1
Abstract 
Objective: To know the common CFTR mutations in the Egyptian patients with cystic fibrosis as it was previously 
thought to be uncommon disease in Egypt.
Methods: This is a cross sectional study of 60 patients diagnosed as cystic fibrosis by sweat chloride testing. They 
were enrolled from the Allergy and Pulmonology Unit Children’s Hospital Cairo University. They were screened for the 
presence of the frequent 36 mutations in Caucasians by reverse hybridization line probe technique, using INNO‑
LiPACFTR19 and CFTR17 + Tn kits.
Results: Most of patients presented with classic manifestations of CF such as variable pulmonary disease and pancre‑
atic insufficiency, and hepatomegaly with or without ascites. The mutations detected were F508 del (58 %), 2183AA/G 
(10 %), N1303K (6 %), I148T (4 %), W1282X (4 %), G155D (2 %), CFTRdel2‑3 (21 KB) (2 %), 3199del6 (2 %), R347P (2 %). 
Unique to the Egyptian population are these mutations R1162X and A544E (6, 4 %) respectively they were found in 
our cohort study and were not reported elsewhere in the Arab population till now. There was no association between 
the initial clinical presentation of CF and the genotypes detected.
Conclusion: The F508 del is still the most commonly encountered mutation (58 %), however other rare mutations 
were identified where each ranged from (2 to 10 %).
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Background
Cystic fibrosis (CF), the most common lethal genetic 
disease in whites, affects approximately 70,000 people 
worldwide (Bethesda 2009). The basic defect in CF cells 
is the faulty chloride transport, which causes dehydra-
tion of secretions with hyper viscous mucus and leads to 
chronic airway obstruction, exocrine pancreatic insuffi-
ciency and intestinal malabsorption. While many organs 
are affected in CF, pulmonary disease is the major cause 
of morbidity and mortality (Lubamba et al. 2012).
Persistent respiratory symptoms, bronchiectasis, or 
clubbing should prompt a diagnostic evaluation for CF. 
Although nasal polyps can be seen in other conditions; 
their presence should suggest the possibility of CF (Voter 
and Clement 2008). The accurate knowledge of CFTR 
(cystic fibrosis Transmembrane conductance regulator) 
mutations is of obvious interest in clinical testing, as it 
improves CF prevention programs of neonatal screen-
ing, heterozygote screening in partners of CF patients or 
partners of carriers. Reporting updated data specifically 
for each group of populations is also crucial for deeper 
understanding of CF genetics (Des Georges et al. 2004).
CFTR mutations vary in their frequency and distribu-
tion in different populations. CF was previously thought 
to be rare among Arabs, however there are some pub-
lished data denoting its existence (Banjar 1999; Farra 
et al. 2010; Siryani et al. 2015).
Our aim in the present study was to detect the com-
mon mutations encountered in a group of Egyptian CF 
population, using the commercially available kits. Better 
understanding of the genetic background of our popula-
tion and its relation to the clinical presentation of CF, will 
allow us for providing optimum care for our patients.
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Subjects and methods
Subjects
This pilot study included 60 CF patients enrolled from to 
the CF clinic of the Allergy and Pulmonology Unit, Chil-
dren’s Hospital Cairo University over a period of 2 years 
(January 2013–January 2015); where these patients 
came regularly for follow up and receiving medications. 
Patients were diagnosed as having CF based on clinical 
presentations and confirmed by sweat chloride testing, 
which was repeated twice as per the cystic fibrosis foun-
dation (CFF) guidelines (Le Grys et al. 2007). Blood sam-
ples were withdrawn for genetic testing of the frequent 
36 mutations in Caucasians (Lenarduzzi et al. 2014).
Quantitative sweat chloride testing
Sweat stimulation was done using the pilocarpine ionto-
phoresis for induction and sweat collection by the Wes-
cor macroduct sweat collection system (NCCLS 2000). 
The sweat sample was analyzed quantitatively by the thi-
ocyanate colorimetric method (Skeggs and Hochstrasser 
1964). Test result higher than 60 mmol/L was considered 
positive and consistent with the diagnosis of CF.
Molecular analysis
DNA was extracted from whole blood samples using 
QIAamp Mini Kit (QIAGEN, USA). All patients with 
positive sweat chloride test were screened for the pres-
ence of the 36 frequent mutations in Caucasians, using 
INNO-LiPACFTR19 and CFTR17  +  Tn kits (Innoge-
netics, Ghent, Belgium). This is a multi parameter line 
probe assay based on the reverse hybridization principle 
for the simultaneous detection and identification of 36 
CF-related mutations and their wild-type sequences in 
human whole blood.
Briefly, multiplex PCR was done in a reagent mix con-
taining biotinylated primers, dNTPs and hot start Taq 
polymerase. Amplification was done according to the 
manufacturer’s protocol: 30 cycles of denaturation at 
95 °C for 1 min, annealing at 57 °C for 1 min, extension at 
68 °C for 1 min, then final extension at 68 °C for 10 min. 
Amplified biotinylated DNA was chemically denatured 
and hybridized with specific oligonucleotide probes 
immobilized on membrane-based strips. Streptavidin 
conjugated with alkaline phosphatase was added to bind 
to any biotinylated hybrid formed. Incubation with a sub-
strate solution containing a specific chromogen resulted 
in a pink color and positive patterns were recorded.
Statistical methods
Data was analyzed using IBM SPSS (software pack-
age used for statistical analysis) Advanced Statistics 
version 20.0 (SPSS Inc., Chicago, IL). Numerical data 
were expressed as mean and standard deviation (SD) or 
median and range as appropriate. Qualitative data were 
expressed as frequency and percentage.
Results
The present study enrolled 60 Egyptian children with 
CF, their age ranged from 6  months to 14  years. Thirty 
eight of them were males and 22 were females. Positive 
consanguinity was reported in 57 % of patients. 23 % of 
patients had positive family history of CF; the most fre-
quent clinical presentations were pulmonary disease 84 % 
followed by pancreatic insufficiency (56 %). Demographic 
and clinical data of the studied population are summa-
rized in Table 1.
Twenty seven out of the 60 patients proved to be 
positive for the 36 mutations searched for. Among the 
120 alleles examined, 50 positive alleles (41.6  %) were 
detected as shown in Table 2.
The most commonly encountered mutations were 
F508del (58 %) followed by 2183AA/G (10 %). Testing of 
intron 8 (T) n variants revealed that the most frequent 
allele was the T7 allele (71.7 %) followed by the T9 allele 
(25.8 %) and the T5 allele (2.5 %). The mean ± (SD) age 
of patients with positive mutational testing was 6.7 (4.3) 
years. Male:Female ratio was 2.6:1. Most of patients 
(24/25) presented with pulmonary disease and pancre-
atic insufficiency. The mean (SD) sweat chloride con-
centration was 87.5 (12.5)  mmol/L; ranging from 69 to 
110 mmol/L. Positive consanguinity was present in 57 % 
of patients. Positive family history was present in 23  % 
of cases. Results of sweat chloride concentrations; geno-
types and phenotypes of the 25 positive patients with are 
given in Table 3.
Table 1 Demographic data and  clinical presentations 
of the study population
Data are presented as number (percent)
a Data are presented as median (range)
Variables N = 60 (%)




Positive family history of CF 14 (23)
Positive consanguinity 34 (57)
Clinical presentations
Pulmonary disease 56 (93)
Pancreatic insufficiency 52 (87)
Hepatic disease 9 (15)
Intestinal obstruction 2 (3)
Nasal polyps 13 (22)
Sinusitis 13 (22)
Pseudo barter 1 (1.66)
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Discussion
Although the most common CFTR mutation is F508del, 
which accounts for 65–85 % of all reported CFTR muta-
tions in Caucasian populations, New and novel muta-
tions have been detected in the Egyptian CF population 
as well as the different Arab communities who carry 
CFTR mutations that had never been described in the 
Caucasians (Farra et al. 2010). Limited data are available 
about CF in Egypt. Only two recently published articles 
highlighted the presence of many cases assuming that it 
is not uncommon in Egypt (Naguib et al. 2007; El-Falaki 
et al. 2014).
Our study addressed the most common CFTR muta-
tions in another 60 CF patients different from those 
included in our previous study (El-Falaki et  al. 2014). 
Most of patients included in the sample had typical 
clinical manifestations of repeated chest infection, vari-
able pulmonary disease, steatorrhea, failure to thrive and 
early liver disease. The mutations detected were F508 del 
(58  %), 2183AA/G (10  %), N1303K (6  %), I148T (4  %), 
W1282X (4 %), G155D (2 %), CFTRdel2-3 (21 KB) (2 %), 
3199del6 (2  %), R347P (2  %). The F508 del represented 
(58 %) of the mutations detected in our study population, 
this was in near frequency to what was found in United 
Arab Emirates and Tunisia where F508del represents 94 
and 50.74 % respectively (Frossard et al. 1998; Messaoud 
et  al. 2005). Where as in other populations like Iran 
F508del was found in only 18 % (Alibakhshi et al. 2008).
Our patients who were homozygous for theF508del 
had severe pulmonary disease, severe PI and liver dis-
ease. These finding were in accordance with Castellani 
et  al. (2008) who showed that Patients homozygous for 
F508del usually have more pronounced clinical mani-
festations compared to compound heterozygotes and 
genotypes without F508del, although these differences 
are highly variable. Patients homozygous for the F508del 
mutation have an earlier diagnosis of disease, higher 
sweat chloride levels, younger age at presentation and are 
more likely to be pancreatic insufficient (Castellani et al. 
2008).
The initial presentation of one female patient was 
pseudo Bartter’s syndrome (PBS) at the age of 6 month 
who later developed chest infection and steatorrhea. 
She was heterozygous for G551D mutation, which is the 
third most common CF-causing mutation, and is pre-
sent in about 4 % of patients (Kotha and Clancy 2013), 
it was found in United Kingdom and central Europe, 
Syria and Egypt. We report here for the first time in the 
literature this mutation in a case of PBS. Another pre-
viously reported mutation in one patient with CF and 
presenting with PBS, severe dehydration and hypochlo-
remic metabolic acidosis in 2011 were (3849  +  1G>A 
and 4382delA compound heterozygosity) (Nahida et  al. 
2011), this was in addition to M2789 + 5G and F508del 
described in 2013 in Jordan (Dahabreh and Najada 
2013) and D575G mutation in southern Italy (Salvatore 
et al. 2004).
The mutation 2183AA/G was encountered in 10  % of 
our studied alleles. It is a frameshift mutation (A to G at 
2183 and deletion of A at 2184). It was encountered in 
similar frequency in Syria and Algeria (Jarjour et al. 2015; 
Loumi et al. 2008). It was also found in Southern Europe, 
Iran, and Latin America (Rolfini and Cabrini 1993). 
Patients who have this mutation had classic clinical mani-
festations of variable pulmonary disease and pancreatic 
insufficiency which agreed with other studies suggesting 
that this phenotype could lead to moderate–severe symp-
toms (Pereira et  al. 1999). The mutations R1162X and 
A544E are present in the Egyptian population in a ratio of 
6 and 4 %, respectively. To our knowledge they were not 
described elsewhere in the Arab population till now.
The mutation R1162X was detected in three patients; 
two were heterozygotes for 2183AA/G/R1162X, but 
with variable pulmonary and pancreatic involvement, 
recurrent nasal polyps and sinusitis. However when 
this mutation R1162X comes with F508 it leads to more 
severe symptoms in addition to liver affection. This is a 
very common nonsense mutation in north eastern Italy 
Table 2 Frequency of mutations detected among the stud-
ied patients
Data are presented as number (percent)
Mutation Allele frequency, 
N = 50 (%)
Class of mutation
ΔF508 29 (58) Class II
Non‑functional, degraded 
mutant CFTR protein
2183AA/G 5 (10) Class I
Shortened protein
N1303K 3 (6) Class II
R1162X 3 (6) Class IV
Reduced chloride con‑
ductance
I148T 2 (4) Alone it is a neutral 
polymorphism not 
causing CF
W1282X 2 (4) Class I
Shortened protein
A544E 2 (4)
G155D 1 (2) Class III
Channel cannot be regu‑
lated properly
CFTRdel2,3 (21 KB) 1 (2) Class I
Shortened protein
3199del6 1 (2) Class II
R347P 1 (2) Class IV
Reduced chloride con‑
ductance
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which usually presents with mild to moderate pulmonary 
disease and severe pancreatic insufficiency (Rolfini and 
Cabrini 1993).
The mutation A544E was detected in one patient as 
homozygous mutation, this patient had mild pulmonary 
disease and PI with failure to thrive. This exceedingly rare 
A455E mutation (identified in only eight patients in the 
United States) is the best described CF-causing mutation 
associated with a mild CF lung phenotype (Walker et al. 
1997). Two Patients having the N1303K mutation either 
homozygous or heterozygous have the same classic clini-
cal presentation of pulmonary affection and pancreatic 
insufficiency. This was in contrast to Van Hoorenbeeck 
et al. (2007) who found that this mutation was associated 
with mild atypical CF disease presenting at variable ages 
(Van Hoorenbeeck et al. 2007).
The mutation I148T was found in a compound het-
erozygotes form with 2183AA/G in one patient and with 
3199del6 in another patient who had rectal prolapse in 
addition to the classic CF pulmonary disease and pan-
creatic insufficiency. This was in accordance to the study 
done in 2004 declaring that I148T exists as a complex 
allele with 3199del6 in patients with clinical CF and rec-
ommended that Reflex testing for 3199del6 should be 
considered whenever I148T is identified (Monaghan 
et al. 2004). The mutation W1282X detected in our study 
was also found in other Arab countries like Lebanon, 
Palestine, Syria, Tunisia and Algeria (Farra et  al. 2010). 
However, it showed a higher frequency than F508del in 
some populations such as Ashkenazi Jews (Shoshani et al. 
1992).
CF patients in our study bearing the W1282X muta-
tion were in compound heterozygote form with F508del. 
They have severe pulmonary and pancreatic disease, this 
was in accordance with Rolfini and Cabrini in 1993 who 
found that CF patients bearing W1282X present severe 
pulmonary and pancreatic disease, whereas patients car-
rying other nonsense mutations such as G542X, R553X, 
Table 3 Demographic, phenotype and genotype characteristics of the 27 patients with positive mutations
Y yes, N no, Pt patient, Y years, M male, F female, FH family history, Pul. Dis. pulmonary disease such as chronic cough, wheezing or recurrent bronchitis, PI pancreatic 
insufficiency, PS pancreatic sufficiency, Hepat. Dis. hepatic disease such as hepatomegaly, ascites. T7, T5 and T9 refer to the allele variants commonly known as IVS8 Tn 
repeats. Homo homozygote, Hetero heterozygote
Pt No Sex Age (Y) Genotype T repeats Sweat chloride Phenotype
1 M 2 Hetero, R347P T7 79 PS/Pul. Dis.
2 F 3 Homo, 2183AA/G T7 69 PI/Pul. Dis.
3 F 4 I148T/3199del6 T7/T9 104 PI/Pul. Dis., Rectal prolapse
4 M 6 Hetero, N1303K T7 71 PI/Pul. Dis.
5 M 7 Homo, DeltaF508 T7 95 PI/Pul. Dis.
6 M 3 Homo, N1303K T7 70 PI/Pul. Dis.
7 M 11 Homo, DeltaF508 T7 104 PI/Pul. Dis./Nasal polyps/sinusitis
8 M 4 Homo, DeltaF508 T7 88 PI/Pul. Dis./Hepat. Dis.
9 F 14 DeltaF508/W1282X T7 90 PI/Pul. Dis.
10 M 5 2183AA/G/R1162X T7 99 PI/Pul. Dis./Nasal polyps
11 M 17 DeltaF508/W1282X T7 100 PI/Pul. Dis.
12 F 3 Homo, DeltaF508 T7 76 PI/Pul. Dis.
13 M 5 Homo, DeltaF508 T7 105 PI/Pul. Dis.
14 F 8 Homo DeltaF508 T7 102 PI/Pul. Dis./Nasal polyps/sinusitis
15 M 7 Homo, DeltaF508 T7 85 PI/Pul. Dis.
16 M 17 2183AA/G/R1162X T7 75 Nasal polyps/sinusitis
17 F 5 Homo, DeltaF508 T7 70 PI/Pul. Dis./Hepat. Dis.
18 F 5 Hetero, CFTR del 2,3 (21 kb) T7 75 PI/Pul. Dis.
19 M 8 Homo, DeltaF508 T7 82 PI/Pul. Dis./sinusitis
20 M 8 Homo, DeltaF508 T7 80 PI/Pul. Dis./Nasal polyps/sinusitis/Hepat. Dis.
21 F 6 I148T/AA2183/G T7 95 PI/Pul. Dis.
22 M 8 Homo, DeltaF508 T7 100 PI/Pul. Dis./Nasal polyps/sinusitis/Hepat. Dis.
23 M 4 DeltaF508/R1162X T9 90 PI/Pul. Dis./Hepat. Dis
24 M 3 Homo, A455E T7 75 PI/Pul. Dis.
25 F 1 Hetero, G551D T7 110 PI/Pul. Dis./Pseudo Barter syndrome
26 M 5 Homo, DeltaF508 T7 80 PI/Pul. Dis./Nasal polyps/sinusitis
27 M 14 Homo, DeltaF508 T7 95 PI/Pul. Dis./Nasal polyps/sinusitis
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S1255X, R1162X, and W1316X show a severe pancreatic 
but mild pulmonary illness (Rolfini and Cabrini 1993).
Our study showed that the mutation R347P was 
detected once (2  %) in a compound heterozygous form 
with unknown other mutations. It occurs with an over-
all worldwide frequency of about 0.2  %. This patient 
had mild pulmonary disease and pancreatic sufficiency, 
which differs from what Vron et al. found during study-
ing a group of 19 CF patients with this mutation of Ger-
man, Bulgarian, Czech, and Slovak origin; where most 
patients presented with early disease onset, pancreatic 
insufficiency and early pulmonary involvement, suggest-
ing that this mutation can lead to a severe course of CF 
(Varon et al. 1995).
The deletion mutation CFTRdel2,3 (21 KB) was found 
in a compound heterozygous form with unknown other 
mutation in another patient with moderate to severe 
pulmonary disease and pancreatic insufficiency. These 
finding agreed with Dork et al. who found that this dele-
tion represents a severe mutation associated with pan-
creatic insufficiency and early age at diagnosis, and that 
the 21-kb deletion is a frequent and severe CF mutation 
in populations of Eastern- and Western-Slavic descent 
(Dork et al. 2000).
Conclusion
This study addressed the CFTR mutations in Egyptian 
patients with cystic fibrosis. The F508 del is the most 
commonly encountered mutation, yet there are some 
mutations that haven’t been described before. Genotype-
phenotype correlation is not always easy to establish; 
genetic explanations are still being sought for differ-
ent clinical manifestations in individuals with identical 
mutations, although the explanation may lie in interplay 
of genetic, infectious, and environmental factors. DNA 
sequencing is required in order to detect further muta-
tions that will provide the basis for neonatal screening 
program as well as prenatal diagnosis.
What is already known?
Cystic Fibrosis is less common in Egypt and may not 
be considered in the differential diagnosis by many 
physicians. Profile of CFTR mutations for Egyptians 
remains unknown.
What this study adds?
The commonest mutation detected in the Egyptians 
with CF was ∆ F508 del (58  %), followed by other 
mutations 2183AA/G (10 %), N1303K (6 %), I148T 
(4  %), W1282X (4  %), G155D (2  %), CFTRdel2-3 
(21 KB) (2 %), 3199del6 (2 %), R347P (2 %).
Limitations of the study
(a) Limited mutation screening panel of 36 mutations 
only was used. It is now known that there are more 
than 2000 CFTR mutations.
(b) It represents single center data and may not reflect 
the prevalence of these mutations in the general 
Egyptian population.
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